with urothelial bladder cancer accounting for approximately 90% of cases. Metastatic UC (mUC) is a particularly aggressive subset that presents significant treatment challenges, especially in patients ...

The research, published in the journal Urologic Oncology: Seminars and Original Investigations, focused on metastatic ...

Genentech has chosen to withdraw the US indication of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC bladder cancer) who are not eligible ...

Clinical responses were seen in urothelial (mUC) and cervical cancer participants in both studies. First-time targeting of head and neck squamous cell carcinoma (HNSCC) in the Western study ...

“Targeting MUC1 with an immunotherapy that elicits a strong and durable tumor-infiltrating T-cell response could represent a major advancement in cancer treatment.” The National Cancer ...